HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 3,200 shares, a growth of 60.0% from the March 31st total of 2,000 shares. Based on an average daily volume of 600 shares, the short-interest ratio is currently 5.3 days.
HLS Therapeutics Stock Performance
HLTRF opened at $3.56 on Friday. The firm has a 50-day moving average price of $3.34 and a 200-day moving average price of $3.35. HLS Therapeutics has a twelve month low of $2.60 and a twelve month high of $4.95.
Analysts Set New Price Targets
Separately, Raymond James dropped their price target on shares of HLS Therapeutics from $6.50 to $5.00 and set a “market perform” rating on the stock in a research report on Monday, March 18th.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Read More
- Five stocks we like better than HLS Therapeutics
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 4/22 – 4/26
- What is the FTSE 100 index?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Buy P&G Now, Before It Sets A New All-Time High
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
